Teva Stalled Generics For Blockbuster MS Drug, Buyers Say
By Hailey Konnath · March 7, 2022, 9:24 PM EST
Teva Pharmaceuticals was hit with a proposed class action Monday, with pharmacies and other purchasers accusing the drugmaker of unlawfully suppressing generic competition for its $3 billion-a-year multiple sclerosis treatment Copaxone by...
To view the full article, register now.